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Summary
Background In accordance with the age parameters specified in Sustainable Development Goal target 3.4, current 
policy and monitoring of non-communicable disease (NCD) mortality trends focus on people aged 30–69 years. This 
approach excludes the majority of NCD deaths, which occur at older ages. We aimed to compare cardiovascular 
mortality for different age groups in the WHO Region of the Americas.
Methods We extracted mortality data from the Pan American Health Organization regional mortality database for 
36 countries for the period 2000 to 2015. We calculated age-standardised mortality rates (ASMRs) from cardiovascular 
diseases for different age groups for these countries. Joinpoint regression models were used to estimate mortality 
trends, providing estimates of the average annual percentage change for the period 2000–15.
Findings Individuals aged 70 years or older accounted for the majority of cardiovascular disease deaths in all countries 
(range 52–82%). Considerable variation in cardiovascular deaths was observed between countries for all age categories. 
Between 2000 and 2015, in most countries, the largest reductions in ASMR were observed in the older age groups 
(aged ≥70 years). The total number of regional cardiovascular disease deaths that hypothetically could have been averted 
in 2015 for people aged 30–79 years was 440 777, of which 211 365 (48%) occurred among people aged 70–79 years.
Interpretation Data for the WHO Region of the Americas are sufficiently robust to permit comparative analysis of 
cardiovascular disease mortality trends for people aged 70 years and older over time and across countries. Although 
the reduction of cardiovascular disease mortality in individuals aged 30–69 years is a valid policy goal for the Americas 
region, this objective should be expanded to include people at older ages.
Funding None.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
The WHO Independent High-level Commission on 
Noncommunicable Diseases has raised justifiable con-
cerns about the slow progress towards reducing 
non-communicable disease (NCD) mortality in all 
WHO regions, including the Region of the Americas.1 
Consistent with the Sustainable Development Goal 
target 3.4, global monitoring of NCD mortality exclusively 
focuses on people aged 30–69 years. For example, 2018 
WHO country NCD profiles2 provide no information on 
mortality among older people (aged ≥70 years). However, 
individ uals aged 70 years and older account for the 
majority of NCD deaths in all WHO regions with the 
exception of Africa, where they account for 38% of all 
NCD deaths.3
The Lancet NCD Countdown 2030 Collaborators4 
observed that NCD targets that exclude certain age groups 
are inconsistent with the wider Sustainable Development 
Goals principle of leaving no one behind, and call for a 
more inclusive approach. The extent to which this is 
possible in different WHO regions is a matter of 
debate. Estimation of cause-specific death rates becomes 
increasingly uncertain at older ages because an increased 
proportion of deaths are coded as due to ill-defined 
causes, multimorbidity is high, and uncertainty exists 
about precise ages recorded in mortality and population 
data sources.5
We aimed to assess the viability of including people 
aged 70 years and older in NCD monitoring for the 
Region of the Americas with reference to cardiovascular 
disease, which is the leading cause of death in the region. 
We examined the distribution of cardiovascular dis-
ease deaths across different age groups, compared age-
standardised mortality rates (ASMRs) for cardiovascular 
disease for different age groups across countries, and 
compared national trends in cardiovascular disease 
ASMRs for different age groups between 2000 and 2015. 
We also considered the implications of our findings for 
health policy targets in the Americas and other regions.
Methods
Data sources
We extracted mortality data from the Pan American 
Health Organization regional mortality database (updated 
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in July, 2017), which comprises deaths registered in 
national vital registration systems and reported annually 
to the Pan American Health Organization by national 
authorities in all 36 countries of the WHO Region of the 
Americas.6 This dataset contains information on sex, age, 
date of death, place of residence, and underlying cause of 
death coded using the International Classification of 
Diseases, tenth revision (ICD-10).7
Quality of data on registered deaths was assessed by 
measuring data completeness, including variables with 
missing values (sex and age with unknown categories), 
and years with no reported data; cause-of-death diag-
nostic and coding quality, by quantifying the proportion 
of death with ill-defined causes of death and so-called 
garbage codes; and estimation of the coverage level 
(appendix p 20). Mortality data were validated according 
to ICD-10 classification standards and corrected to 
overcome data quality issues following standard 
methods.8 Briefly, underlying cause-of-death codes are 
validated against a list of accepted mortality codes and 
verified against age and sex restrictions. Deaths with 
unknown sex or age were redistributed pro rata among 
deaths with known sex and ages. Deaths with underlying 
causes coded as ill-defined causes of death (ICD-10 codes 
R00–R94 or R96–R99) were redistributed proportionally 
among deaths with non-injury causes of death by strata 
of country, year, sex, and age group. Deaths with 
underlying causes coded as events of undetermined 
intent (ICD-10 codes Y10–Y34) were redistributed 
proportionally among deaths due to in juries. Registered 
deaths for countries with estimated under-registration 
higher than 3% and available data in the WHO life table8 
were corrected according to their level of under-
registration by strata of year, sex, age, and underlying 
cause of death. After addressing data quality issues, the 
number of deaths was estimated by country, sex, age 
group, and four-digit code of cause-of-death for the 
whole time period (2000–15) with reported data as part 
of annual estimation cycles.
We used mid-year population estimates obtained from 
a database that integrates data from the World Population 
Prospects, 2017 Revision9 (for countries with population 
size of 90 000 or more) and data from the US Census 
Bureau International Database10 (for countries and 
territories with population of less than 90 000) to 
calculate death rates. The WHO Standard11 was used to 
calculate ASMRs. Deaths due to cardiovascular disease 
were defined as all deaths classified using ICD-10 codes 
I00–I99.
11 countries and territories with a population size of 
less than 90 000 were excluded from the analysis. 
Additionally, Bolivia, Haiti, and Honduras were excluded 
because of low data quality and poor data completeness 
(appendix p 20). Overall, the countries and territories 
excluded represent only 3% of the total population of the 
Americas.
Data analysis
We calculated the number of cardiovascular disease 
deaths by 5-year age group and sex, and the proportion 
of cardiovascular disease deaths by age group (0–30, 
30–49, 50–69, 70–79, and ≥80 years), by broader age 
group (30–69 and ≥70 years), and by sex. We com-
puted age-specific and sex-specific death rates from 
cardiovascular disease per 100 000 person-years for 
5-year age groups (0–4, 5–9, 10–14, ..., 75–79, 80–84, and 
≥85 years) for men, women, and both sexes combined. 
We also computed the cardiovascular disease age-stand-
ardised death rates per 100 000 person-years at all ages 
and for age groups 30–49, 50–69, 70–79, and 80 years 
and older, and age groups 30–69 and 70 years and older 
in men, women, and both sexes combined by the direct 
method. We used the Joinpoint Regression Program 
(version 4.5.0.1) to assess mortality trends over time, 
where by models provided estimates of the average 
annual percentage change (AAPC) and 95% CIs for the 
period 2000–15 using age-standardised death rate as the 
depen dent variable and year as the independent variable. 
Analysis of trends via estimation of conventional annual 
percent change in age-adjusted rates by fitting a simple 
linear model of the logarithm of annual age-adjusted 
rates regressed on time, and transforming the slope to 
determine the percent change per year is easy to calculate 
and understand. However, this is not a reliable estimate 
Research in context
Evidence before this study
Numerous published studies report that in most countries in 
the WHO Region of the Americas mortality due to cardiovascular 
disease has decreased in the past 20 years. Before initiating this 
study, we did a broad review of MEDLINE and relevant policy 
documents, which identified no published studies that focused 
on people older than 70 years or compared mortality between 
older and younger age groups.
Added value of this study
This is the first study to compare age-standardised 
cardiovascular disease mortality across different age groups for 
the Region of the Americas, using the most recent data 
available (up to 2015).
Implications of all the available evidence
Between 2000 and 2015, in the Region of the Americas, 
reductions in cardiovascular disease mortality were larger 
among older age groups (aged ≥70 years) than younger age 
groups (aged <70 years), albeit with large national variations, 
suggesting that a large proportion of deaths among people 
70 years or older are avoidable. Consequently, individuals aged 
70 years and older should not be excluded from global health 
targets, several of which aim to reduce premature mortality.
See Online for appendix
For more on Joinpoint software 
see https://surveillance.cancer.
gov/joinpoint/
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if the rate of change over time is not constant. 
In such circumstances many studies now estimate 
the AAPC using Joinpoint, which provides segmented 
analysis of rates over the entire time period.12,13 Each 
p value is calculated using the Monte Carlo method,14 
and the overall asymptotic significance level is 
maintained through a Bonferroni correction. We used 
4499 randomly permuted datasets (default setting in the 
Joinpoint software). These tests also consider situations 
with non-constant variance to account for rates with 
Poisson variation and possibly autocorrelated errors. 
The AAPC is a summary measure of the trend over a 
prespecified fixed interval, which is computed as a 
weighted average of the annual percent change from the 
Joinpoint model, with the weights equal to the length 
of the annual percent change interval. The AAPC is 
considered statistically significant when its value differs 
from zero at α level 0·05. To interpret the AAPC, a 
constant trend was considered when the zero value was 
within the lower and upper limits of the 95% CI of the 
AAPC; an increasing trend was considered present 
when both limits of the 95% CI were positive, and a 
decreasing trend was considered present when both 
limits of the 95% CI were negative.
Incidence rates were compared with those in Canada 
and presented as incidence rate ratios.
To determine the number of cardiovascular disease 
deaths that could have hypothetically been avoided, 
we compared the actual number of deaths in 2015 with 
the expected number of deaths that would have occurred 
assuming there was no change in ASMRs between 2000 
and 2015.
Figure 1: Cardiovascular disease deaths by age group in adults aged 30 years and older in selected countries and territories of the Americas, 2013–15
34 of 36 countries or territories had available data for the period 2013–15.
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Role of the funding source
There was no funding source for this study. The corre-
sponding author had full access to all the data in 
the study and had final responsibility to submit for 
publication.
Results
We analysed data from 36 countries. Individuals aged 
70 years or older accounted for the majority of cardio-
vascular disease deaths in all countries, ranging from 
52% in the Bahamas to 82% in Martinique (figure 1). 
The proportion of cardiovascular disease deaths in the 
30–49 year age group was highest in the Bahamas (15%) 
and lowest in Canada (3%).
ASMR varied considerably between countries across all 
age categories (table 1). For all age categories, the highest 
incidence rates relative to Canada were observed for 
Guyana (incidence rate ratio 6·3 for individuals aged 
30–49 years; 7·0 for individuals aged 50–69 years; 5·9 for 
individuals aged 70–79 years; and 3·8 for individuals 
aged ≥80 years). Countries with the lowest incidence rate 
ratios relative to Canada varied by age group (1·3 for 
Year* 30–49 years 50–69 years 70–79 years ≥80 years
ASMR Incidence rate 
ratio† 
(95% CI)
ASMR Incidence 
rate ratio† 
(95% CI)
ASMR Incidence rate 
ratio† 
(95% CI)
ASMR Incidence rate 
ratio† 
(95% CI)
Antigua and Barbuda 2015 84·2 5·2 (3·6–7·6) 354·2 2·8 (2·1–3·6) 1180·4 2·0 (1·5–2·8) 5622·2 2·1 (1·7–2·6)
Argentina 2014 31·5 1·9 (1·8–2·1) 275·0 2·1 (2·1–2·2) 1154·4 2·0 (1·9– 2·0) 4059·4 1·5 (1·5–1·6)
Aruba 2015 25·2 1·6 (0·8– 3·1) 244·7 1·9 (1·5–2·4) 1049·1 1·8 (1·4–2·3) 4997·2 1·9 (1·6–2·3)
The Bahamas 2013 98·7 6·1 (5·0– 7·4) 350·9 2·7 (2·4–3·1) 1302·7 2·2 (1·9–2·6) 3927·6 1·5 (1·3–1·7)
Barbados 2013 54·9 3·4 (2·5– 4·5) 276·4 2·2 (1·9–2·5) 1035·9 1·8 (1·5–2·1) 4603·6 1·7 (1·6–1·9)
Belize 2014 48·6 3·0 (2·2– 4·1) 408·8 3·2 (2·7–3·8) 2532·9 4·3 (3·7–5·1) 7673·1 2·9 (2·5–3·4)
Brazil 2015 48·0 3·0 (2·8– 3·1) 327·9 2·6 (2·5–2·6) 1278·5 2·2 (2·2–2·2) 4012·1 1·5 (1·5–1·5)
Canada 2013 16·2 1·0 (1·0–1·0) 128·0 1·0 (1·0–1·0) 582·5 1·0 (1·0–1·0) 2646·9 1·0 (1·0–1·0)
Chile 2015 21·6 1·3 (1·2– 1·4) 182·5 1·4 (1·4–1·5) 842·9 1·4 (1·4–1·5) 3180·3 1·2 (1·2–1·2)
Colombia 2013 35·6 2·2 (2·1– 2·3) 331·0 2·6 (2·5–2·6) 1522·3 2·6 (2·6– 2·7) 4705·2 1·8 (1·8–1·8)
Costa Rica 2014 26·1 1·6 (1·4– 1·8) 204·4 1·6 (1·5–1·7) 936·8 1·6 (1·5–1·7) 3466·2 1·3 (1·3–1·4)
Cuba 2015 32·3 2·0 (1·9– 2·1) 311·9 2·4 (2·4–2·5) 1367·0 2·3 (2·3–2·4) 4129·0 1·6 (1·5–1·6)
Dominican Republic 2013 59·1 3·6 (3·4– 3·9) 504·0 3·9 (3·8–4·1) 1843·7 3·2 (3·1–3·3) 4864·5 1·8 (1·8–1·9)
Ecuador 2015 33·9 2·1 (1·9– 2·2) 216·9 1·7 (1·6– 1·8) 901·5 1·5 (1·5–1·6) 3791·1 1·4 (1·4–1·5)
El Salvador 2014 37·4 2·3 (2·1– 2·5) 203·1 1·6 (1·5–1·7) 829·2 1·4 (1·4–1·5) 4209·1 1·6 (1·5–1·6)
French Guiana 2014 26·6 1·6 (1·0– 2·6) 190·7 1·5 (1·2–1·9) 803·4 1·4 (1·0–1·9) 2472·5 0·9 (0·7–1·2)
Grenada 2015 95·3 5·9 (3·8– 9·0) 613·7 4·8 (3·9–5·9) 2201·7 3·8 (3·0–4·7) 7137·0 2·7 (2·3–3·2)
Guadeloupe 2014 22·7 1·4 (1·0– 2·0) 135·9 1·1 (0·9–1·2) 607·4 1·0 (0·9–1·2) 2489·7 0·9 (0·9–1·0)
Guatemala 2015 36·7 2·3 (2·1– 2·4) 243·9 1·9 (1·8–2·0) 973·5 1·7 (1·6–1·7) 4244·1 1·6 (1·6–1·6)
Guyana 2013 101·7 6·3 (5·4– 7·3) 890·0 7·0 (6·5–7·5) 3464·1 5·9 (5·5–6·5) 10 077·4 3·8 (3·5–4·2)
Jamaica 2011 46·8 2·9 (2·6– 3·2) 257·8 2·0 (1·9–2·1) 1254·8 2·2 (2·0–2·3) 4588·4 1·7 (1·7–1·8)
Martinique 2014 26·8 1·7 (1·1– 2·4) 114·3 0·9 (0·7–1·1) 496·1 0·9 (0·7–1·0) 2967·7 1·1 (1·0–1·2)
Mexico 2015 31·0 1·9 (1·8– 2·0) 235·5 1·8 (1·8– 1·9) 1070·7 1·8 (1·8–1·9) 3788·0 1·4 (1·4–1·4)
Nicaragua 2015 44·3 2·7 (2·5–3·0) 318·3 2·5 (2·4–2·6) 1304·1 2·2 (2·1–2·4) 4721·9 1·8 (1·7–1·8)
Panama 2015 32·1 2·0 (1·8– 2·2) 238·2 1·9 (1·8– 2·0) 975·7 1·7 (1·6–1·8) 3612·3 1·4 (1·3–1·4)
Paraguay 2014 45·2 2·8 (2·5– 3·1) 332·9 2·6 (2·5– 2·7) 1280·9 2·2 (2·1–2·3) 5057·4 1·9 (1·8–2·0)
Peru 2015 28·5 1·8 (1·7– 1·9) 165·1 1·3 (1·3– 1·3) 765·9 1·3 (1·3–1·4) 2531·0 1·0 (0·9–1·0)
Puerto Rico 2015 23·7 1·5 (1·3–1·7) 177·7 1·4 (1·3–1·5) 737·7 1·3 (1·2–1·3) 2421·7 0·9 (0·9–0·9)
Saint Lucia 2014 56·1 3·5 (2·4– 5·0) 410·8 3·2 (2·7– 3·8) 1471·6 2·5 (2·1–3·1) 4942·8 1·9 (1·6–2·1)
Saint Vincent and the Grenadines 2015 50·9 3·1 (1·9– 5·2) 338·9 2·6 (2·1–3·4) 2000·4 3·4 (2·7– 4·3) 8270·0 3·1 (2·7–3·7)
Suriname 2014 68·6 4·2 (3·5– 5·2) 518·3 4·0 (3·7– 4·5) 2196·4 3·8 (3·4–4·2) 5537·2 2·1 (1·9–2·3)
Trinidad and Tobago 2011 69·6 4·3 (3·8– 4·9) 522·4 4·1 (3·9–4·3 2179·4 3·7 (3·5– 4·0) 6483·1 2·4 (2·3–2·6)
USA 2015 37·3 2·3 (2·2– 2·4) 233·9 1·8 (1·8– 1·9) 834·8 1·4 (1·4– 1·5) 3488·5 1·3 (1·3–1·3)
Uruguay 2015 26·2 1·6 (1·4– 1.9) 250·5 2·0 (1·9–2·1) 1075·7 1·8 (1·8–1·9) 3690·8 1·4 (1·4–1·4)
Venezuela 2013 47·2 2·9 (2·8– 3·1) 378·2 3·0 (2·9–3·0) 1748·3 3·0 (2·9–3·1) 5300·6 2·0 (2·0–2·0)
Virgin Islands 2015 36·0 2·2 (1·2–4·3) 268·3 2·1 (1·7–2·6) 520·2 0·9 (0·7–1·2) 3233·7 1·2 (1·0–1·5)
Data are number of deaths per 100 000 person-years. ASMR=age-standardised mortality rate. *Last year data was available. †Relative to Canada.
Table 1: Cardiovascular disease mortality across countries and territories of the Americas by age group
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individuals aged 30–49 years in Chile; 0·9 for individuals 
aged 50–69 years and individuals aged 70–79 years in 
Martinique; and 0·9 for individuals aged ≥80 years in 
Puerto Rico).
Between 2000 and 2015, ASMRs decreased in most 
countries for all age categories (table 2), which reflects the 
regional trend, although wide variation was observed 
between countries. Of the more populous countries in the 
Region of the Americas, Mexico stands out in terms of the 
limited progress made. Large disparities were identified 
among smaller countries, although the robustness of 
the data is limited by small population sizes. Between 
2000 and 2015, the cardiovascular disease ASMRs in all 
age groups in Brazil, Canada, Colombia, Mexico, and the 
USA general ly decreased, with the exception of Mexico, 
and the largest reductions were observed in the older age 
groups (70–79 years and ≥80 years; figure 2). ASMR data 
for all countries are shown in the appendix (p 10).
Table 3 presents the number of cardiovas cular disease 
deaths by age group that could have hypotheti cally been 
averted for selected countries. Hypothetically, for the 
region as a whole, in 2015, 440 777 cardiovascular disease 
Period 30–49 years 50–69 years 70–79 years ≥80 years
Antigua and Barbuda 2000–15 5·9 (–2·2 to 14·5) –1·0 (–3·1 to 1·0) –2·4 (–3·6 to –1·2) –0·4 (–1·8 to 1·1)
Argentina 2000–14 –3·7 (–4·5 to –2·9) –2·6 (–2·9 to –2·2) –2·2 (–2·6 to –1·9) –2·0 (–2·4 to –1·6)
Aruba 2000–15 –4·1 (–6·5 to –1·6) –3·3 (–5·4 to –1·1) –4·3 (–8·6 to 0·3) –1·7 (–3·7 to 0·4)
The Bahamas 2000–13 4·4 (0·1 to 8·8) –0·6 (–2·4 to 1·2) –2·2 (–3·4 to –0·9) –2·8 (–4·3 to –1·3)
Barbados 2000–13 1·9 (–1·0 to 4·8) –1·9 (–3·2 to –0·6) –3·0 (–4·3 to –1·6) –2·4 (–3·0 to–1·8)
Belize 2000–14 –5·1 (–7·6 to –2·4) –5·8 (–9·0 to –2·6) –5·1 (–9·5 to –0·5) –1·1 (–2·5 to 0·3)
Bermuda 2000–15 2·3 (–2·2 to 7·1) –3·6 (–7·3 to 0·2) –4·9 (–7·3 to –2·4) –5·6 (–7·6 to –3·5)
Brazil 2000–15 –2·9 (–3·2 to –2·6) –2·9 (–3·0 to –2·7) –2·9 (–3·1 to –2·8) –4·1 (–4·3 to –3·9)
Canada 2000–13 –2·1 (–2·6 to –1·6) –3·8 (–4·1 to –3·5) –4·8 (–5·2 to –4·4) –4·2 (–4·4 to –4·0)
Chile 2000–15 –0·7 (–1·2 to –0·2) –2·2 (–2·5 to–1·9) –2·9 (–3·2 to–2·6) –1·6 (–2·0 to –1·1)
Colombia 2000–13 –1·7 (–2·1 to –1·3) –2·2 (–2·9 to –1·5) –2·0 (–2·3 to –1·7) –2·3 (–2·7 to –1·9)
Costa Rica 2000–14 –1·6 (–2·7 to –0·5) –1·6 (–2·2 to –1·0) –2·3 (–3·0 to –1·7) –2·1 (–2·5 to –1·7)
Cuba 2001–15 –2·1 (–3·4 to –0·8) –1·9 (–2·3 to –1·5) –2·0 (–2·5 to –1·5) –1·7 (–2·3 to –1·0)
Curaçao 2001–07 2·2 (–8·2 to 13·8) 0·4 (–6·8 to 8·1) 4·8 (–1·1 to 11·1) 0·2 (–7·0 to 8·0)
Dominican Republic 2000–13 –1·6 (–3·0 to –0·2) –0·4 (–1·5 to 0·7) –0·4 (–1·3 to 0·6) 0·3 (–0·9 to 1·5)
Ecuador 2000–15 –4·1 (–4·6 to –3·6) –2·8 (–3·2 to –2·4) –2·5 (–3·0 to –2·1) –1·2 (–2·1 to –0·3)
El Salvador 2000–14 –1·4 (–2·1 to –0·6) –2·5 (–3·0 to –1·9) –4·1 (–4·6 to –3·7) –3·6 (–4·2 to –3·0)
French Guiana 2001–14 –4·1 (–7·3 to –0·8) –3·7 (–5·7 to –1·6) –4·2 (–6·9 to –1·4) –6·0 (–8·5 to –3·4)
Grenada 2002–15 –1·3 (–5·2 to 2·8) –1·0 (–2·4 to 0·4) –0·3 (–2·0 to 1·4) –0·1 (–2·8 to 2·6)
Guadeloupe 2000–14 –2·9 (–5·1 to –0·7) –4·8 (–6·3 to –3·3) –5·6 (–6·5 to –4·6) –3·6 (–4·2 to –3·0)
Guatemala 2005–15 –2·1 (–3·2 to –0·9) 0·1 (–1·0 to 1·2) 0·3 (–0·6 to 1·1) –1·1 (–1·8 to –0·4)
Guyana 2000–13 6·0 (3·7 to 8·4) 1·1 (–0·5 to 2·6) 3·3 (1·7 to 4·8) 1·6 (–3·1 to 6·4)
Jamaica 2000–11 –3·9 (–7·1 to –0·7) –3·1 (–4·0 to –2·2) –2·0 (–2·3 to –1·7) –1·7 (–2·2 to –1·2)
Martinique 2000–14 –1·3 (–3·8 to 1·3) –4·1 (–5·4 to –2·7) –5·7 (–6·6 to –4·7) –2·4 (–4·0 to –0·8)
Mexico 2000–15 0·0 (–1·0 to 1·1) –0·9 (–1·1 to –0·7) 0·1 (–0·2 to 0·4) –0·8 (–1·2 to –0·5)
Nicaragua 2000–15 –2·6 (–3·7 to –1·4) –2·8 (–3·5 to –2·2) –2·6 (–3·1 to –2·1) –2·4 (–3·0 to –1·7)
Panama 2000–15 0·4 (–0·3 to 1·2) –0·8 (–1·5 to –0·1) –1·8 (–2·4 to –1·3) –1·7 (–2·1 to –1·3)
Paraguay 2000–14 –2·9 (–4·2 to –1·5) –2·5 (–3·6 to –1·4) –2·4 (–4·0 to –0·8) –2·3 (–3·7 to –0·8)
Peru 2000–15 –1·5 (–2·3 to –0·7) –1·9 (–2·5 to –1·4) –2·2 (–2·7 to –1·7) –3·1 (–3·6 to –2·5)
Puerto Rico 2000–15 –2·6 (–3·3 to –1·8) –3·1 (–3·5 to –2·7) –3·1 (–3·5 to –2·8) –2·3 (–2·6 to –2·0)
Saint Lucia 2000–14 –0·6 (–4·0 to 3·1) –1·3 (–3·2 to 0·6) –1·5 (–3·3 to 0·3) –0·7 (–1·8 to 0·5)
Saint Vincent and the Grenadines 2000–15 0·6 (–2·4 to 3·7) 1·4 (–0·3 to 3·2) 1·3 (–0·3 to 3·0) 1·7 (–2·7 to 6·4)
Suriname 2000–14 –3·7 (–4·8 to –2·6) –3·3 (–5·6 to –1·0) –2·4 (–3·8 to –0·9) –2·9 (–5·3 to –0·4)
Trinidad and Tobago 2000–11 –3·8 (–7·4 to 0·0) –3·1 (–3·6 to –2·6) –1·7 (–3·1 to –0·3) –0·2 (–2·5 to 2·0)
USA 2000–15 –1·1 (–1·3 to –0·8) –2·3 (–2·6 to –2·0) –3·5 (–3·8 to –3·2) –3·0 (–3·4 to –2·5)
Uruguay 2000–15 –3·3 (–3·8 to –2·8) –2·9 (–3·2 to –2·6) –2·9 (–3·4 to –2·3) –2·9 (–3·5 to –2·3)
Venezuela 2000–13 –3·0 (–3·4 to –2·6) –1·6 (–2·2 to –1·1) –1·6 (–1·9 to –1·3) –0·3 (–0·7 to 0·1)
Virgin Islands 2000–15 –4·4 (–7·9 to –0·9) –2·4 (–4·2 to –0·5) –5·9 (–7·9 to –3·9) –3·8 (–5·4 to –2·2)
Data are AAPC (95% CI). Negative AAPC estimates represent a reduction in age-standardised cardiovascular death rate. Bermuda and Curaçao have been included because all 
countries and territories with available data for the specified time periods were included. AAPC=average annual percentage change.
Table 2: AAPC in age-standardised cardiovascular mortality rate by age group for selected countries and territories of the Americas, 2000–15
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deaths in people aged 30–79 years could have been 
averted, of which 211 365 (48%) occurred among people 
aged 70–79 years.
Discussion
Cardiovascular disease continues to be the leading cause of 
all deaths in the WHO Region of the Americas, accounting 
for 1·6 million deaths annually.3 Around two-thirds of 
these deaths occur among people aged 70 years and over, 
reflecting the rate of demographic and epidemiological 
transition in most countries. The proportion of the 
population aged older than 70 years is expected to increase 
from 5·6% in 2000 to 10·5% by 2030.9
Available data for the Region of the Americas are 
sufficiently robust to permit comparative analysis of 
cardiovascular disease mortality trends over time, across 
countries, and between age groups. This includes the 
population aged 70–79 years and, to a lesser extent, 
people aged 80 years and older, indicating the viability of 
including these groups in targets and monitoring.
Our findings are consistent with previous studies 
of the Americas region, which report a 19% decline 
Figure 2: Level and trends of age-standardised cardiovascular disease death rates by sex and age group in selected countries of the Americas, 2000–15
ASMR=age-standardised mortality rate.
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in cardiovascular disease mortality at all ages and a 
21% decline for people younger than 70 years between 
2000 and 2010.15,16 These findings are also consistent 
with a separate analysis of the WHO mortality data-
base,17 which shows that reduced cardiovascular disease 
mortality at older ages was one of the most important 
contributors to overall improvements in life expectancy 
among older populations in low-income and middle-
income countries between 1980 and 2010. Although 
trends in age-specific cardiovascular disease mortality 
based on ASMR show a clear reduction between 2000 and 
2015, the total number of people with cardiovascular 
disease and associated mortality has increased, re-
sulting in a higher burden on health services. Globally, 
the absolute number of cardiovascular disease deaths 
increased by 41% between 1990 and 2013, of which half 
is attributed to population ageing and a quarter to 
population growth, with similar trends observed in 
the Americas region, highlighting the importance of 
including older people in NCD policies.18
Despite the regional trend of decreasing age-specific 
cardiovascular disease mortality, large national disparities 
exist. Variations are to be expected between countries with 
small populations, as a result of the small numbers of 
observations. However, we also observed variation between 
countries with larger populations, such as Chile and 
Colombia. This is consistent with the findings of a global 
study of age-specific cardiovascular disease mortality,18 
which reported large variations between countries.
The drivers of trends in cardiovascular disease mortality 
might differ between countries and require further study, 
particularly in a region as heterogeneous as the Americas. 
Future research should focus on modifiable risk factors 
associated with both prevention and treatment. Available 
data do not permit comparative analysis of risk factors 
or associated policies. However, it is possible to make 
some broad observations. First, a number of risk factors, 
especially hypertension, increase in prevalence with age 
and relative risks usually persist into at least the eighth 
decade of life. Consequently, tackling risk factors such as 
uncontrolled hypertension lowers mortality in older people 
to a similar extent as that in younger people.19–21 Second, 
increasing evidence suggests that improved access to 
effective treatment can reduce mortality. A Swedish study22 
reported a sustained decline in 28-day case fatality between 
1994 and 2010 for older individuals admitted to hospital 
for myocardial infarction, stroke, and other cardiovascular 
conditions in people aged up to 99 years. However, in 
many countries older people continue to be treated much 
less intensively than younger people.23,24
Reducing cardiovascular disease death rates in older 
people prevents many more deaths than does a similar 
reduction in younger people, since mortality is higher in 
older populations than younger populations. Individuals 
aged 70–79 years accounted for nearly half of all deaths that 
could have hypothetically been averted in the Americas 
region between 2000 and 2015. This finding calls into 
question the exclusive focus of global NCD targets on 
people aged 30–69 years and supports calls from The Lancet 
NCD 2030 Countdown Collaborators for more inclusive 
monitoring.4 More generally, our findings demonstrate 
that describing the deaths of people younger than 70 years 
as premature (ie, implying that less can, or should, be done 
to avert deaths at older ages) has no scientific foundation 
and might lead to discrimination.
There are a number of approaches that could be used in 
concurrence with premature mortality to track progress in 
reducing mortality from cardiovascular disease and other 
causes. One approach would be to raise the threshold 
30–49 years 50–69 years 70–79 years ≥80 years
Antigua and Barbuda –18 4 18 –1
Argentina 2419 9750 9076 18 137
Aruba 5 79 77 46
The Bahamas –56 41 58 160
Barbados 6 81 104 179
Belize 23 268 120 86
Brazil 16 190 66 809 50 692 114 607
Canada 484 8077 12 323 27 678
Chile 192 2423 3493 4054
Colombia 1453 9004 6846 11 380
Costa Rica 110 568 710 1208
Cuba 438 3208 3072 4572
Dominican Republic 494 225 207 –627
Ecuador 1042 2247 1975 1929
El Salvador 137 880 1810 3180
French Guiana 11 35 22 35
Grenada 5 20 17 25
Guadeloupe 9 100 170 355
Guatemala 336 –106 –59 641
Guyana –99 –290 –225 –106
Jamaica 175 461 392 758
Martinique 2 114 183 214
Mexico 176 5216 –265 4856
Nicaragua 358 981 831 1263
Panama –28 223 277 738
Paraguay 425 1284 936 1476
Peru 762 2746 3179 6219
Puerto Rico 116 784 974 1387
Saint Lucia 9 –4 18 75
Saint Vincent and the Grenadines 2 1 –8 –39
Suriname 95 243 134 200
Trinidad and Tobago 55 691 404 284
USA 5185 74 888 108 806 221 915
Uruguay 173 834 1007 2168
Venezuela 1880 4906 3901 1249
Virgin Islands 11 46 89 80
Overall 32 576 196 836 211 365 430 382
The number of avoidable deaths were calculated based on the assumption that age-standardised mortality rate 
remained the same between 2000 and 2015.
Table 3: Avertable cardiovascular disease deaths in 2015, by age group in selected countries of the Americas
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for what is categorised as a premature death, perhaps to 
80 years of age. This is the approach taken by the NCD 
2030 Countdown Collaborators.4 However, across the 
region of the Americas substantial reductions were 
observed in ASMRs for cardiovascular disease for people 
80 years and older. Establishing a cutoff for health targets 
at any age contradicts the view that good health care is a 
universal right and the Sustainable Development Goals 
principle of leaving no one behind.
A more suitable approach would be to complement 
or replace the premature mortality targets with a target 
to re duce avoidable deaths among people of all ages. 
These tar gets would combine amenable mortality 
(deaths avoid able through appropriate personal health-
care interventions) and preventable mortality (control 
of risk factors). A study of 51 countries17 estimated that 
38% of deaths occurring in men aged 60 years or older 
and 29% of deaths in women aged 60 years or older 
in 2011 were avoidable. Of those avoidable deaths, 
72% occurred among people older than 70 years. 
Estimates of avoidable mortality are possible even in 
countries with low-quality civil registration data and do 
not require an arbitrary age threshold.
Alternatively, the quantification of premature mortality 
could be complemented by measuring years of life lost 
(YLLs) due to premature death. YLLs are calculated by 
subtracting age at death from the longest life expectancy 
observed for a person at that age in any territory with a 
population of more than 5 million.25 Thus, if the longest 
life expectancy observed at age 72 years was 86 years, the 
YLLs for someone dying at this age would be 14 years. 
Emerging evidence26 suggests that this approach can be 
effectively applied to NCD mortality trends in regions 
such as the Americas.
This study has a number of limitations. Death data are 
not available for country-years without reported data. 
Consequently, we used an incomplete series of mortality 
estimates for the study period for some countries. The 
mortality correction processes do not include the 
redistribution of some cause of death considered so-called 
garbage codes. This could minimally affect the analysis, 
since heart failure (ICD-10 code I50) represents 15% of all 
garbage codes in the Americas that are included as 
cardiovascular disease (ICD-10 codes I00–I99). 11 countries 
and territories were excluded from the analysis because of 
small populations and three were excluded because of data 
quality issues. However, these exclusions do not invalidate 
the results because the level and trends of mortality were 
analysed by country, and the excluded countries and 
territories represented a small proportion of the total 
population of the Americas. Additionally, we did not 
calculate 95% uncertainty intervals for ASMRs by age 
group because we did not use a sample population to 
calculate the ASMRs. However, we corrected the registered 
deaths to overcome data quality issues. Despite these 
limitations, the mortality estimates and results from the 
comparative analysis are valid and robust, and demonstrate 
country-level reductions in cardiovascular disease mortality 
for adults of all age groups in the Americas.
Decreasing cardiovascular disease mortality among 
adults of all ages in the Americas should not lead to 
complacency. Without sustained action to reduce risk 
factors through better prevention and treatment this 
decrease in mortality might level out, as observed in the 
USA.27 Although the reduction of cardiovascular disease 
mortality in individuals aged 30–69 years is a valid policy 
goal for the Region of the Americas, this objective should 
be expanded to include people at older ages.
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